Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.94 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.80 |
| ▸ | F2 | P00734 | 1/20 | 0.80 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL87622 | 0.97 | F10 (1.00) | F10ABCB11F2ST14 | |
| SCHEMBL78812 | 0.97 | F10 (1.00) | F10ABCB11F2ST14 | |
| SCHEMBL2986836 | 0.92 | F10 (0.82) | F10ABCB11F2ST14 | |
| Rivaroxaban SCHEMBL3914 | 0.89 | F10 (1.00) | F10ABCB11F2ST14 | |
| Rivaroxaban SCHEMBL7721848 | 0.89 | F10 (1.00) | F10ABCB11F2ST14 | |
| Rivaroxaban SCHEMBL77766 | 0.89 | F10 (1.00) | F10ABCB11F2ST14 | |
| SCHEMBL77782 | 0.89 | F10 (0.86) | F10ABCB11F2ST14 | |
| SCHEMBL77206 | 0.88 | F10 (1.00) | F10 | |
| SCHEMBL3262953 | 0.88 | F10 (0.74) | F10ABCB11F2ST14 | |
| Rivaroxaban SCHEMBL14796329 | 0.88 | F10 (0.98) | F10ABCB11F2ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140050743-A1 | BINDING PROTEINS TO INHIBITORS OF COAGULATION FACTORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-20 | — | — | US | disclosed |
| EP-2665751-A1 | BINDING PROTEINS TO INHIBITORS OF COAGULATION FACTORS | Bayer Intellectual Property GmbH (DE) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012098089-A1 | BINDING PROTEINS TO INHIBITORS OF COAGULATION FACTORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-26 | — | — | WO | disclosed |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | Bayers Schering Pharma Aktiengesellschaft (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | Bayers Schering Pharma Aktiengesellschaft (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | Bayers Schering Pharma Aktiengesellschaft (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | Bayers Schering Pharma Aktiengesellschaft (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20100273789-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273789-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273789-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| CN-101730695-A | Aminoacyl prodrugs as an active pharmaceutical ingredient for thromboembolic disorders | BAYER HEALTHCARE AG | 2010-06-09 | — | — | CN | disclosed |
| EP-2167500-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | Bayer Schering Pharma AG (DE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009007026-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007026-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007027-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007027-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008155034-A1 | SUBSTITUTED OXAZOLIDINONES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | XDH, OXA1L, PPOX | F10 391/4885ABCB11 725/4885F2 39/4885 |
| US-20140050743-A1 | BINDING PROTEINS TO INHIBITORS OF COAGULATION FACTORS | F13B, F11, SERPINC1 | F10 10/4885ABCB11 3023/4885F2 8/4885 |
| US-20110172232-A1 | AMINOACYL PRODRUGS AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THROMBOEMBOLIC DISORDERS | AADAC, AADAT, AASDHPPT | F10 126/4885ABCB11 2339/4885F2 15/4885 |
| US-20100273789-A1 | AMINOACYL PRODRUGS | AADAC, DNPEP, AADAT | F10 735/4885ABCB11 1495/4885F2 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.